With the biosimilar regulatory pathway in sight in markets around the world, companies from the biopharma innovators to traditional small molecule generic houses to well-funded start-ups are exploring how they can enter the biosimilar business. A biosimilar strategy can be either defensive or offensive, depending on the company's position. Countries
in Asia, particularly India, Singapore, Korea and China, are attractive locations to build biosimilar capabilities. This panel will discuss the resources and infrastructure already in place in these countries, what some of the companies are already doing, and how these might impact the biologics markets of United States and Western Europe.

• Provide overview of the current industry infrastructure, investment incentives and regulatory framework, and key participants in India, Singapore, Korea and China
• Profile examples of companies already building their biosimilar capabilities in these Asian countries
• Discuss the likely impact on the biolgics market of the United States and Western Europe